Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022286 | 0.82 | TSHR (0.75) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL2303831 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL29505877 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL1388248 | 0.80 | TSHR (0.73) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL574702 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL29381539 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL514422 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL29597389 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL5181305 | 0.80 | TSHR (0.41) | TSHRNPSR1KDM1A | |
| Hydrochloric Acid SCHEMBL5439604 | 0.79 | TSHR (1.00) | TSHRNPSR1SLC6A2SLC6A4PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-7723384-B2 | Keto lactam compounds and use thereof | ABBOTT GMBH & CO. KG. (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | OPRD1, DRD3, OPRK1 | TSHR 236/4885NPSR1 105/4885SLC6A2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.